Description: Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.
Home Page: www.enlivex.com
ENLV Technical Analysis
14 Einstein Street
Ness Ziona,
7403618
Israel
Phone:
972 8 662 3301
Officers
| Name | Title |
|---|---|
| Mr. Shai Novik M.B.A. | Exec. Chairman |
| Dr. Oren Hershkovitz Ph.D. | Chief Exec. Officer |
| Prof. Dror Mevorach M.D. | Founder and Chief Scientific & Medical Officer |
| Ms. Shachar Shlosberger CPA | Chief Financial Officer |
| Ms. Sigal Arad | Director of HR |
| Mr. Veronique Amor-Baroukh | Head Of CMC |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Information Technology |
|---|---|
| GIC Group: | Software & Services |
| GIC Industry: | Software |
| GIC Sub-Industry: | Application Software |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2047 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 1995-12-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 71 |